Welcome to our dedicated page for In8Bio SEC filings (Ticker: INAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IN8bio, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing γδ T cell therapies and γδ T cell engagers. Form 8-K reports cover operating and financial results, clinical updates for INB-200 and INB-400 in newly diagnosed glioblastoma, preclinical γδ T cell engager data, financing and capital-structure matters, and governance events.
Proxy materials describe annual-meeting voting matters, director elections, auditor ratification, equity incentive plan proposals, board oversight, executive compensation, and stockholder governance. The filings also identify INAB common stock registered on Nasdaq and provide formal records of material events affecting the company's pipeline, financing, and corporate governance.
IN8bio, Inc. reported that its Chief Financial Officer, Patrick McCall, received an employee stock option grant for 56,250 options to buy common stock at an exercise price of $1.58 per share. Following this grant, he holds 56,250 derivative securities directly.
The option vests in four equal parts, with 25% of the shares vesting on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, as long as he continues providing service through each vesting date. The option expires on May 9, 2036.
IN8BIO, INC. reported that President and COO Kate Rochlin received a grant of employee stock options covering 60,000 shares of common stock. The options have an exercise price of $1.58 per share and expire on May 9, 2036.
These compensation-related options were awarded with no cash paid by the executive at grant. According to the vesting schedule, 25% of the option shares vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, as long as she continues providing service through each date. After this grant, she holds options for 60,000 underlying shares directly.
IN8BIO, INC. director Corinne Epperly received a grant of stock options covering 22,000 shares of Common Stock. The options have an exercise price of $1.58 per share and expire on May 9, 2036, and represent a compensation-related award rather than an open-market trade.
One twelfth of the options vest in equal monthly installments starting on June 9, 2026, with full vesting no later than the company’s next annual meeting of stockholders, as long as she continues providing service through each vesting date.
IN8BIO, INC. director Peter C. Brandt received a grant of stock options covering 22,000 shares of common stock at an exercise price of $1.58 per share. The options vest in equal monthly installments over 12 months starting on June 9, 2026, and any unvested portion becomes fully vested on the date of the company’s next annual stockholder meeting, subject to continued service. Following this grant, Brandt holds 22,000 stock options directly.
IN8BIO, INC. director Jeremy R. Graff received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $1.5800 per share and expire on May 9, 2036. One-twelfth of the options vest monthly starting June 9, 2026, or they become fully vested on the date of the company’s next annual stockholder meeting if he continues providing service.
IN8bio, Inc. reports Q1 2026 results and highlights substantial doubt about its ability to continue as a going concern. The clinical-stage biotech posted a net loss of $5.1 million, slightly improved from $5.6 million a year earlier, as operating expenses fell to $5.3 million.
Cash was $21.9 million as of March 31, 2026, which management expects to fund operations only into April 2027. With an accumulated deficit of $146.2 million and no product revenue, the company plans to prioritize its pipeline, seek additional equity or debt financing, and pursue collaborations.
IN8bio’s programs include INB-100 for high-risk leukemias, INB-200/400 for glioblastoma, and INB-619, a CD19-targeted T cell engager for autoimmune diseases, though several preclinical efforts remain paused to conserve cash.
IN8bio, Inc. reported first quarter 2026 results and highlighted progress in its γδ T cell pipeline. Net loss was $5.1 million, or $0.26 per share, compared with a $5.6 million loss a year earlier, as R&D expenses fell modestly to $2.6 million.
Updated clinical data in newly diagnosed glioblastoma showed median progression-free survival of 13.0 months for repeat-dose patients versus 6.6 months for standard-of-care, and median overall survival of 17.2+ months versus 13.2 months, with no dose-limiting toxicities or cytokine release syndrome reported.
Stockholders approved the Amended and Restated 2026 Equity Incentive Plan, adding 2,920,000 shares available for awards, extending the annual share increase through 2037, and setting a 20,000,000-share cap for incentive stock options. Director nominees and the independent auditor were also ratified by wide margins.
IN8bio, Inc. is calling a virtual 2026 annual stockholder meeting on May 7, 2026, to elect two Class II directors, ratify CohnReznick LLP as auditor, and approve an Amended and Restated 2026 Equity Incentive Plan.
As of the March 18, 2026 record date, 9,847,089 shares of common stock were outstanding and entitled to vote. The new 2026 equity plan would authorize 4,054,937 shares for awards, including 2,920,000 new shares plus remaining and returning shares from prior plans, and features an automatic annual share increase formula tied to common shares and pre-funded warrants outstanding.
IN8bio, Inc. files its annual report describing a focused gamma‑delta T cell therapy pipeline alongside a going concern warning. The company is developing allogeneic and autologous gamma‑delta T cell products and T cell engagers for cancers and autoimmune diseases, highlighted by INB‑100 for high‑risk leukemias and INB‑200/INB‑400 for newly diagnosed glioblastoma.
Early clinical data show durable remissions in AML patients after haploidentical transplants and extended progression‑free survival in glioblastoma versus standard therapy. IN8bio reported cash of $27.1 million as of December 31 2025 and expects this to fund operations only into April 2027, leading management to state substantial doubt about its ability to continue as a going concern without additional capital or strategic transactions.